Creditor relations
Creditor Relations
Financing strategy
The Asklepios Group's financing strategy has the following key objectives:
- Ensuring solvency at all times
- Guaranteeing financial flexibility and independence
- Limiting refinancing risks
- Optimizing the weighted average cost of capital
This is achieved through a balanced maturity profile with a high proportion of medium to long-term financing, diversification of financing instruments, and the provision of sufficient free credit lines and liquidity reserves.
Investment highlights
Attractive acute care market
- Long-term, rising demand for healthcare services, independent of economic cycles
Predictability
- Regulated environment with high barriers to market entry
Digital HealthyNear
- Asklepios is a pioneer in the digitalization of healthcare
- Integration and digitalization of treatment methods and processes as an opportunity for growth
Profitability
- Attractive synergy potential through deeper integration and proven operational excellence
- Potential through centralization and profiling of existing healthcare facilities
- Consistent strategic expansion of the value chain, e.g., through e-health solutions
Conservative financing approach
- Healthy financing structure with a balanced maturity profile
- Uncommitted lines of credit ensure a high degree of flexibility
Experience
- Experienced management team
- 35-year history as a successful market consolidator
Promissory notes
Promissory notes, which are placed with various investors for terms of up to 10 years, are an important medium- to long-term financing instrument. In addition, long-term registered bonds with terms of up to 20 years are issued. As of December 31, the Asklepios Group's promissory note loans were composed as follows:
Tabular presentation of the promissory notes of Asklepios
Commercial paper program
Short-term financing requirements will be covered by issues under the commercial paper program newly established in December 2022. Under the commercial paper program, bearer bonds totaling EUR 500.0 million with terms of up to 364 days may be issued in the future.
- Issuer: Asklepios Kliniken GmbH & Co. KGaA
- Program amount: EUR 500 million
- Arranger: Commerzbank AG
- Dealers: BNP Paribas, Commerzbank AG, DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Landesbank Baden-Württemberg, Landesbank Hessen-Thüringen
- Issuing and paying agent: Commerzbank AG
- Maturities: up to 364 days
- Stock exchange admission/listing: not listed
Social Finance Framework
As part of the further integration of sustainability endeavours within the Asklepios Group, a Social Finance Framework was adopted in August 2024.